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Purpose/Objective: Locally-advanced pancreatic 
adenocarcinoma (LAPC) has a poor prognosis with up to 30% 
progressing locally following chemoradiotherapy (CRT). From 
surgical series, it is known that pancreatic tumours are 
hypoxic. As tumour hypoxia is associated with 
chemoradioresistance, selective radiotherapy dose escalation 
to a known hypoxic subvolume may improve rates of local 
control and spare excess toxicity to adjacent normal tissue. 
Fluoromisonidazole is selectively reduced and retained in 
hypoxic cells and its uptake correlates with needle electrode 
measured hypoxia. However, there have been no reports of 
the successful application of FMISO-PET/CT in pancreatic 
cancer. We assessed the utility of 18F-fluoromisonidazole 
(FMISO)-PET/CT for characterising hypoxia in LAPC with the 
aim of generating spatially consistent biological target 
volumes (BTVs) that could be used for radiotherapy dose 
escalation. 
Materials and Methods: 6 patients from an ethically-
approved clinical trial in LAPC had 2 FMISO-PET/CTs 6-7 days 
apart in the week prior to starting CRT.The GTV was defined 
on contrast-enhanced CT (CECT) with the patient 
immobilised in the radiotherapy treatment position. This 
position was replicated for FMISO-PET/CT scanning. The CECT 
was rigidly registered to the CT component of the FMISO-
PET/CTs, prioritising matching of the tumour. The GTV was 
propagated to the FMISO-PET/CTs. FMISO uptake 
quantification and tumour segmentation were performed 
using the PET image acquired 4 hours post-tracer injection. 
The SUVpeak (the 1cm3 sphere volume of interest (VOI) with 
the highest mean activity within the GTV) at each timepoint 
was delineated. The centre of mass of the GTV on both 
FMISO-PET/CTs was aligned and the distance between the 
centres of mass of the SUVpeak at both time points was 
calculated. A hypoxic boost volume was segmented on the 
second FMISO-PET/CT, using the thresholds tumour:muscle 
(T:M) >1.3 and tumour:blood (T:B) >1.4 . 
Results: The mean tumour volume was 23.0 cm3 (range 11.3-
34.9 cm3). There was no significant difference in maximum, 
mean or median SUV, T:M or T:B between scans when 
quantified across the whole GTV or the SUVpeak VOI. The mean 
distance between the centres of mass of the SUVpeak on the 
two FMISO-PET/CTs was 2.4 mm (range 0.5-6.8 mm). It was 
less than 3mm in 5/6 patients which is similar to the spatial 
resolution of the PET scan. The subvolumes defined by a 
T:M>1.3 and T:B>1.4 covered a mean of 34.8% (range 1.8-
83.4%) and 14.6% (range 0.8-42%) of the GTV respectively. 
Conclusions: To our knowledge, this is the first report of 
sequential FMISO-PET/CT successfully characterising hypoxia 
in LAPC. Our proposed method of segmenting the tumour to 
delineate a hypoxic BTV produces volumes that are smaller 
than the GTV, but large enough to allow for dose escalation. 
The region of peak FMISO-uptake is spatially consistent over 
6-7 days. 
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Purpose/Objective: In rectal cancer patients treated with 
radiotherapy, prediction models could help to calculate 
probabilities for various outcomes, e.g. pathologic complete 
remission (pCR), disease-free survival, or various toxicities. 
Although model development and validation in trials can 
determine the performance of prediction models, we cannot 
expect the same performance in clinical practice. Not only 
because trial datasets do not necessarily represent the 
clinical population, but also because prediction model 
features are not always readily available in clinical practice 
and need to be (often manually) extracted from multiple 
sources. In this abstract, we present a semi-automatic 
method to collect features for prediction model application 
in clinical practice. As a secondary aim, we apply this method 
to validate a rectal cancer pCR prediction model (PMID: 
21176986) in routine clinical data. 
Materials and Methods: We started by identifying the sources 
of the prediction model features. The clinical and 
pathological TNM stages could be found in the electronic 
medical record (EMR). The tumor length was based on 
magnetic resonance imaging (MRI), and therefore only 
available in the free text diagnostic MRI report. The second 
step involved extracting features from the source systems 
(EMR and free text reports), and storing them in a Semantic 
Web data store. We used the Radiation Oncology Ontology 
(ROO) as our standardized terminology, in combination with 
Semantic Web technology to link extracted data from both 
sources (Figure 1). In the third step, we executed a query on 
the extracted data, and applied the prediction model on the 
query result. Finally, the area under the Receiver Operating 
Characteristic curve (AUC) was calculated to determine the 
discriminative power of the prediction model. 
 
 
Results: After querying our data store, we found 2579 rectal 
cancer patients, where 38 patients matched all features and 
outcomes (clinical and pathological TN, and tumor length) to 
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perform the validation (Table 1). Our validation resulted in 
an AUC of 0.62. The AUC increased to 0.76 after we removed 
all duplicate patients due to multiple false-positive tumor 
length 'hits' per patient during automated free text 
search.
 
 
Conclusions: We describe a method to extract data from 
multiple sources, and to apply a prediction model on routine 
clinical patient data. Although the free text extraction was 
not perfect and the number of patients in our validation was 
low (N=38), we have successfully shown a method for 
automatically (nightly) applying prediction models in clinical 
practice, and thus enabling use of prediction results for 
treatment decisions. Unfortunately, there is still a need to 
enhance data collection at the source. For example, the 
availability of pCR was our most limiting factor (only 4% of 
patients). Furthermore, the extraction of tumor length from 
free text reports remains necessary until available in a 
structured format. 
Based on this method, future work consists of adding more 
data sources and routine clinical validation of prediction 
models.  
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Purpose/Objective: A re-organisation of surgery of rectal 
cancer among reference hospitals was implemented in 2011 
based on the results of a clinical audit. The aim of this study 
was to assess the impact of centralization of rectal cancer 
surgery on radiotherapy patterns of care and its impact on 
clinical outcomes. 
Materials and Methods: Quality of rectal cancer care was 
assessed by means of a clinical audit (retrospective cohort 
study) of all patients receiving treatment for rectal cancer 
with a radical intent in public hospitals in Catalonia in two-
time periods (2005/7 and 2011/12). Radiotherapy patterns of 
care as well as clinical outcomes, comparing both periods, 
were analysed in order to measure the impact of 
centralization. Clinical practice was compared with evidence-
based clinical guidelines.  
Results: From 2005/7 to 2011/12 the number of hospitals 
performing rectal cancer surgery decreased from 51 to 29. 
The study covered 2553 patients with TNM stage-II or III 
primary rectal cancer. From 2005/7 to 2011/12 the number 
of patients receiving radiotherapy for their rectal cancer, 
either pre o postoperatively, has increased from 72.2 to 
76.2% (p=0.025). Delivering pre-operative radiotherapy ± 
chemotherapy (RT/ChT) increased from 57.3 to 66.2% 
(p<0.001). Short course radiotherapy increased from 2% to 
7%. 
When comparing patient characteristics broken down by 
neo(adjuvant) treatment, patients with pre-operative 
RT/ChT are marked by: a younger age; a lower surgical risk 
and a tumour site more frequently located in the distal 
rectum, and this in both periods. 
The crude local recurrence rate at 1 year of follow-up was 
3.1%.  
The results of the univariate COX regression analyse showed a 
local-recurrence rate hazard ratio of 1.9 for the group of 
patients that did not receive any radiotherapy versus the 
group that received preoperative radiotherapy (p=0.019). In 
the multivariate COX regression analysis, TNM stage, type of 
neo(adjuvant) treatment and type of surgical intervention 
were independent predictors of risk of local recurrence at 1 
year of follow-up. 
Further follow-up is ongoing. 
Conclusions: Centralising surgery into high volume providers 
could be associated with improved adherence to radiotherapy 
recommendations, possibly as a result of more structured 
multidisciplinary decisions.  
Health policy approach combining assessment from the 
clinical audit with reorganisation of the delivery of complex 
treatments has been associated with better outcomes. A 
model of care based on the centralisation of high-complexity 
cancer treatments should be supported by managed regional 
networks and improved referral of patients.  
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Purpose/Objective: Intensity modulated radiotherapy 
(IMRT), including volumetric arc therapy (VMAT) and helical 
IMRT (HT) techniques, has been only recently introduced in 
the treatment of anal canal cancer patients. We 
retrospectively assessed efficacy and safety of IMRT, VMAT, 
HT and daily image-guided RT (IGRT) for anal canal cancer. 
Materials and Methods: Data of patients with a diagnosis of 
anal canal squamous-cell carcinoma treated with curative 
intent in two academic radiation oncology departments were 
analyzed. Local control (LC) and grade 3 or more toxicity rate 
(CTC-AE v.4.0) were the primary endpoints. Overall (OS), 
disease-free (DFS), and colostomy-free survival (CFS) are also 
reported. Anal canal, mesorectal, pelvic, and inguinal nodes 
received a total dose of 36 Gy (1.8 Gy/fr) using IMRT or VMAT 
or HT (depending on the treating center). A sequential boost 
to the anal canal and positive nodes (total dose: 59.4-60 
Gy,1.8-2 Gy/fr) was delivered with IMRT, VMAT, HT or 3D-
conformal RT (CRT). Planning target volume was obtained 
adding 5-mm margin to the clinical target volume. 
Results: Between 03.2006 and 05.2014, a total of 137 
patients was treated; 15, 62, 31 and 28 patients presented 
